Cyclerion is leveraging knowledge of cyclic-GMP (cGMP) to address serious CNS diseases. Using their systems biology approach, Cyclerion has identified CNS diseases in which the NO-sGC-cGMP pathway plays a central role including both neurodegenerative and neuropsychiatric diseases. These diseases are associated with deficits in the NO-sGC-cGMP. By developing sGC stimulators, such as CY6463, Cyclerion is hoping to restore disrupted signaling while maintaining endogenous NO regulation. CY6463 is Cyclerion’s first CNS-penetrant sGC stimulator that has shown benefits in multiple animal models by improving neuronal function, reducing neuro-inflammation and enhancing cellular bioenergetics. CY6463 is now in clinical trials.

Cyclerion Therapeutics

Founded: 2019
Location: Cambridge, MA
Employee range: 11 - 50
Clinical stage: Clin1b/Clin2a
Therapy area: Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes
Drug types: CVV, NEU, GEN, RAR, PSY
Lead product: CY6463
Funding: $18M stock Jun 2021; $24M stock Jul 2020

Drug notes:

About:

Jobs: